91 related articles for article (PubMed ID: 35214639)
1. Low Neutralizing Antibody Titers against the Mu Variant of SARS-CoV-2 in 31 BNT162b2 Vaccinated Individuals in Colombia.
Álvarez-Díaz DA; Muñoz AL; Tavera-Rodríguez P; Herrera-Sepúlveda MT; Ruiz-Moreno HA; Laiton-Donato K; Franco-Muñoz C; Pelaez-Carvajal D; Cuellar D; Muñoz-Suarez AM; Galindo M; Arias-Ramírez EJ; Mercado-Reyes M
Vaccines (Basel); 2022 Jan; 10(2):. PubMed ID: 35214639
[TBL] [Abstract][Full Text] [Related]
2. Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine.
Melo-González F; Soto JA; González LA; Fernández J; Duarte LF; Schultz BM; Gálvez NMS; Pacheco GA; Ríos M; Vázquez Y; Rivera-Pérez D; Moreno-Tapia D; Iturriaga C; Vallejos OP; Berríos-Rojas RV; Hoppe-Elsholz G; Urzúa M; Bruneau N; Fasce RA; Mora J; Grifoni A; Sette A; Weiskopf D; Zeng G; Meng W; González-Aramundiz JV; González PA; Abarca K; Ramírez E; Kalergis AM; Bueno SM
Front Immunol; 2021; 12():747830. PubMed ID: 34858404
[TBL] [Abstract][Full Text] [Related]
3. Neutralizing Antibody Responses Elicited by Inactivated Whole Virus and Genetic Vaccines against Dominant SARS-CoV-2 Variants during the Four Epidemic Peaks of COVID-19 in Colombia.
Álvarez-Díaz DA; Muñoz AL; Herrera-Sepúlveda MT; Tavera-Rodríguez P; Laiton-Donato K; Franco-Muñoz C; Ruiz-Moreno HA; Galindo M; Catama JD; Bermudez-Forero A; Mercado-Reyes M
Vaccines (Basel); 2022 Dec; 10(12):. PubMed ID: 36560554
[TBL] [Abstract][Full Text] [Related]
4. Cross-neutralization of SARS-CoV-2 B.1.1.7 and P.1 variants in vaccinated, convalescent and P.1 infected.
Gidari A; Sabbatini S; Bastianelli S; Pierucci S; Busti C; Monari C; Luciani Pasqua B; Dragoni F; Schiaroli E; Zazzi M; Francisci D
J Infect; 2021 Oct; 83(4):467-472. PubMed ID: 34320390
[TBL] [Abstract][Full Text] [Related]
5. mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 Omicron variant.
Edara VV; Manning KE; Ellis M; Lai L; Moore KM; Foster SL; Floyd K; Davis-Gardner ME; Mantus G; Nyhoff LE; Bechnak S; Alaaeddine G; Naji A; Samaha H; Lee M; Bristow L; Hussaini L; Ciric CR; Nguyen PV; Gagne M; Roberts-Torres J; Henry AR; Godbole S; Grakoui A; Sexton M; Piantadosi A; Waggoner JJ; Douek DC; Anderson EJ; Rouphael N; Wrammert J; Suthar MS
bioRxiv; 2021 Dec; ():. PubMed ID: 34981056
[TBL] [Abstract][Full Text] [Related]
6. Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History.
Tarkowski M; de Jager W; Schiuma M; Covizzi A; Lai A; Gabrieli A; Corbellino M; Bergna A; Ventura CD; Galli M; Riva A; Antinori S
Front Immunol; 2021; 12():793191. PubMed ID: 34975897
[TBL] [Abstract][Full Text] [Related]
7. Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines.
Yang Y; Zang J; Xu S; Zhang X; Yuan S; Wang H; Lavillette D; Zhang C; Huang Z
Viruses; 2021 Jul; 13(8):. PubMed ID: 34452287
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Antibody Response Elicited by ChAdOx1 and BNT162b2 COVID-19 Vaccine.
Kang YM; Minn D; Lim J; Lee KD; Jo DH; Choe KW; Kim MJ; Kim JM; Kim KN
J Korean Med Sci; 2021 Nov; 36(46):e311. PubMed ID: 34845875
[TBL] [Abstract][Full Text] [Related]
9. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the Neutralizing Antibodies Response against 14 SARS-CoV-2 Variants in BNT162b2 Vaccinated Naïve and COVID-19 Positive Healthcare Workers from a Northern Italian Hospital.
Sammartino JC; Cassaniti I; Ferrari A; Giardina F; Ferrari G; Zavaglio F; Paolucci S; Lilleri D; Piralla A; Baldanti F; Percivalle E
Vaccines (Basel); 2022 Apr; 10(5):. PubMed ID: 35632457
[TBL] [Abstract][Full Text] [Related]
11. Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants.
Choi A; Koch M; Wu K; Dixon G; Oestreicher J; Legault H; Stewart-Jones GBE; Colpitts T; Pajon R; Bennett H; Carfi A; Edwards DK
J Virol; 2021 Nov; 95(23):e0131321. PubMed ID: 34549975
[TBL] [Abstract][Full Text] [Related]
12. Molecular and Epidemiological Characterization of Emerging Immune-Escape Variants of SARS-CoV-2.
Miyakawa K; Jeremiah SS; Yamaoka Y; Koyama T; Tokumasu R; Kudo M; Kato H; Ryo A
Front Med (Lausanne); 2022; 9():811004. PubMed ID: 35223905
[TBL] [Abstract][Full Text] [Related]
13. Omicron variant susceptibility to neutralizing antibodies induced in children by natural SARS-CoV-2 infection or COVID-19 vaccine.
Chen LL; Chua GT; Lu L; Chan BP; Wong JS; Chow CC; Yu TC; Leung AS; Lam SY; Wong TW; Tsang HW; Wong IC; Chan KH; Yuen KY; Ip P; Kwan MY; To KK
Emerg Microbes Infect; 2022 Dec; 11(1):543-547. PubMed ID: 35084295
[TBL] [Abstract][Full Text] [Related]
14. Antibody titers against the Alpha, Beta, Gamma, and Delta variants of SARS-CoV-2 induced by BNT162b2 vaccination measured using automated chemiluminescent enzyme immunoassay.
Kato H; Miyakawa K; Ohtake N; Go H; Yamaoka Y; Yajima S; Shimada T; Goto A; Nakajima H; Ryo A
J Infect Chemother; 2022 Feb; 28(2):273-278. PubMed ID: 34857462
[TBL] [Abstract][Full Text] [Related]
15. Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants.
Groß R; Zanoni M; Seidel A; Conzelmann C; Gilg A; Krnavek D; Erdemci-Evin S; Mayer B; Hoffmann M; Pöhlmann S; Liu W; Hahn BH; Beil A; Kroschel J; Jahrsdörfer B; Schrezenmeier H; Kirchhoff F; Münch J; Müller JA
EBioMedicine; 2022 Jan; 75():103761. PubMed ID: 34929493
[TBL] [Abstract][Full Text] [Related]
16. BNT162b2-elicited neutralization of Delta plus, Lambda, Mu, B.1.1.519, and Theta SARS-CoV-2 variants.
Liu J; Liu Y; Xia H; Zou J; Weaver SC; Swanson KA; Cai H; Cutler M; Cooper D; Muik A; Jansen KU; Sahin U; Xie X; Dormitzer PR; Shi PY
NPJ Vaccines; 2022 Apr; 7(1):41. PubMed ID: 35396516
[TBL] [Abstract][Full Text] [Related]
17. Correlation between Commercial Anti-RBD IgG Titer and Neutralization Titer against SARS-CoV-2 Beta Variant.
Poon RW; Lu L; Fong CH; Ip TC; Chen LL; Zhang RR; Yip CC; Cheng VC; Chan KH; Yuen KY; To KK
Diagnostics (Basel); 2021 Nov; 11(12):. PubMed ID: 34943453
[TBL] [Abstract][Full Text] [Related]
18. Infection and vaccine-induced neutralizing antibody responses to the SARS-CoV-2 B.1.617.1 variant.
Edara VV; Lai L; Sahoo MK; Floyd K; Sibai M; Solis D; Flowers MW; Hussaini L; Ciric CR; Bechnack S; Stephens K; Mokhtari EB; Mudvari P; Creanga A; Pegu A; Derrien-Colemyn A; Henry AR; Gagne M; Graham BS; Wrammert J; Douek DC; Boritz E; Pinsky BA; Suthar MS
bioRxiv; 2021 May; ():. PubMed ID: 34013272
[TBL] [Abstract][Full Text] [Related]
19. Reduced binding and neutralization of infection- and vaccine-induced antibodies to the B.1.351 (South African) SARS-CoV-2 variant.
Edara VV; Norwood C; Floyd K; Lai L; Davis-Gardner ME; Hudson WH; Mantus G; Nyhoff LE; Adelman MW; Fineman R; Patel S; Byram R; Gomes DN; Michael G; Abdullahi H; Beydoun N; Panganiban B; McNair N; Hellmeister K; Pitts J; Winters J; Kleinhenz J; Usher J; O'Keefe JB; Piantadosi A; Waggoner JJ; Babiker A; Stephens DS; Anderson EJ; Edupuganti S; Rouphael N; Ahmed R; Wrammert J; Suthar MS
bioRxiv; 2021 Feb; ():. PubMed ID: 33655254
[TBL] [Abstract][Full Text] [Related]
20. Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naïve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients.
Trougakos IP; Terpos E; Zirou C; Sklirou AD; Apostolakou F; Gumeni S; Charitaki I; Papanagnou ED; Bagratuni T; Liacos CI; Scorilas A; Korompoki E; Papassotiriou I; Kastritis E; Dimopoulos MA
BMC Med; 2021 Aug; 19(1):208. PubMed ID: 34420521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
